Skip to main content

Sarah Bhagat

Sarah Bhagat, Partner, Sofinnova Investments

  • Sarah Bhagat is a Partner at Sofinnova Investments, where she focuses on biopharmaceutical investments
  • Sarah is currently a member of the board of directors of Inozyme (INZY) and a Board Observer for Aeovian, Antiva, Neurana, and NorthSea. She previously served as a Board Member for Promedior (acquired by Roche for up to $1.4B)
  • Sarah received her Ph.D. in Neuroscience from Yale University working with thesis advisor Dr. Stephen Strittmatter.